OLIVIA EDWARDS: Open Payments
NPI 1780207795 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$684 in 32 payments from 13 companies in 2025. Trend: 2023 $2,053 · 2024 $1,983 · 2025 $684
Food & beverage: $684
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $163 |
| GENZYME CORPORATION | 2 | $80 |
| Janssen Biotech, Inc. | 3 | $74 |
| PFIZER INC. | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $63 |
| QOL Medical, LLC | 2 | $47 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| Aimmune Therapeutics, Inc. | 2 | $42 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
| Gilead Sciences, Inc. | 1 | $22 |
Products named: DUPIXENT, TREMFYA, XELJANZ, ENTYVIO, RINVOQ, SKYRIZI, Sucraid, XIFAXAN.
Industry payments across MO — which companies pay providers there.
